P180 Women with hand osteoarthritis (OA) show higher levels of pain, higher scores of fibromyalgia-like symptoms and more mental distress compared to women with rheumatoid arthritis (RA)  by unknown
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Conclusions: Our preliminary results confirm that self-reported 
knee instability was experienced by most of the subjects with 
MKOA and that individuals with MKOA use higher muscle co- 
contraction in muscles surrounding the knee in response to a 
destabilizing event. With a larger sample size we hope to de- 
termine the influence of self-reported knee instability, as well as 
quadriceps femoris strength, on the muscle activation strategies 
in people with MKOA. 
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KNEE JOINT INJECTION ALTERS QUADRICEPS MUSCLE 
FUNCTION IN RATS 
SM Ling ~ , CJ Galban 2, CJ Galban 2, DD Taub 3, RG Spencer 2 
Clinical Research Branch, Translational Medicine Section, 
National Institute on Aging Intramural Research Program 
(NIA-IRP), Baltimore, MD; 2Laboratory of Clinical Investigation, 
NIA-IRR Baltimore, MD; 3Laboratory of Immunology, NIA-IRR 
Baltimore, MD 
Study Aim: To test the hypothesis that knee joint intervention 
with papain, saline and empty needle injections alter quadriceps 
muscle function as assessed by 3~ p nuclear magnetic resonance 
spectroscopy (NMRS) and measurement of contractile force. 
Methods:  Adult female F344 rats were injected with 20mL of ei- 
ther papain solution (PAP: n= 7) or saline (SAL: n= 9) oran empty 
syringe (IN J: n=9) on days 1,4 and 7 were compared with control 
animals (CTL: n=6). Quadriceps muscle NMRS was performed 
on day 15 with a 1.9 T, 31 cm Bruker ABX Biospec. The muscle 
was directly stimulated using a pair of rectangular pulses each of 
duration 5 ms, with an interval between the pulses of 200 ms and 
an interval between the pulse pairs of 2 s. Spectra were recorded 
with an interpulse delay of 1 s and flip angle of 90 ° for 1 minute. 
A total of 25 spectra were acquired at baseline (2), during elec- 
trical stimulation (8) and recovery to baseline (15). The ratio of 
phosphocreatine to the sum of phosphocreatine and inorganic 
phosphate [PCr/(PCr+Pi)], muscle oxidative capacity (Vm) and 
pH were obtained from the 3~ p data. Contractile force was mea- 
sured with a force transducer and is expressed relative to initial 
force. H & E stained joint sections were scored for severity of 
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cartilage degradation. Two-way repeated-measures ANOVA was 
used to compare the metabolite ratios and relative force during 
stimulation and early recovery periods between groups. ANOVA 
was used for all other analyses. Statistical significance was as- 
sessed at P<0.05. Data are shown as mean 4- SEM. 
Results: As shown in Figure A, the PCr/(PCr+Pi) ratio decreased 
more rapidly with more rapid fatigue during electrical stimulation 
and remained lower during early recovery in IN J, SAL and PAP 
groups compared to CTL (p<0.05). Quadriceps muscles also 
exhibited more rapid fatigue in all treatment groups than CTLs 
(p<0.05) (Figure B). At 8-minutes of stimulation, pH was signif- 
icantly lower in all of the intervention groups compared to CTL, 
while relative oxidative capacity was significantly lower in PAP 
and SAL groups than INJ and CTL (p<0.05). Significant cartilage 
degradation was observed in the PAP but not in either SAL or INJ 
specimens. 
Conclusions: These results suggest that knee joint injection de- 
pletes quadriceps muscle metabolic reserve and causes acceler- 
ated fatigue observable with sustained electrical stimulation with- 
out significant differences in magnitude or time course between 
intervention groups. These changes were induced independent 
of cartilage degradation. 
This work was completely supported by the National Institute on 
Aging Intramural Research Program. 
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WOMEN WITH HAND OSTEOARTHRITIS (OA) SHOW 
HIGHER LEVELS OF PAIN, HIGHER SCORES OF 
FIBROMYALGIA-LIKE SYMPTOMS AND MORE MENTAL 
DISTRESS COMPARED TO WOMEN WITH RHEUMATOID 
ARTHRITIS (RA) 
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Rheumatology, Diakonhjemmet Hospital, Oslo, Norway 
Aim of Study: Different dimensions of health related quality of life 
(HRQoL) as pain and other disease related symptoms represent 
major problems for patients with OA as well as for patients with 
RA. The aim of this study was to compare self reported health 
status and perception of fibromyalgia-like symptoms between fe- 
male OA and RA patients. 
Methods:  One hundred and ninety patients with hand OA and 
194 with RA between 50 and 70 years of age, referred to our 
rheumatology department within the preceding two years, un- 
derwent a comprehensive clinical examination including comple- 
tion of several self-reported health status questionnaires. Among 
these were AIMS2, SF-36 (also used to compute the utility mea- 
sure SF-6D), MHAQ, HAQ, pain, fatigue, patient global on vi- 
sual analogue scales (VAS) and self-efficacy scales. Also in- 
corporated were VAS to score headache, muscular tenderness, 
numbness of the fingers and concentration problems. All patients 
completed identical questionnaires. We present crude values, 
since similar scores were found after adjustment for potential con- 
Mean (SD) scores of selected health status measures in hand OA and RA 
OA (SD) RA (SD) p-value 
(n=190) (n=194) 
Pain scales 
AIMS2 5.63 (2.3) 4.78 (2.5) 0.001 
SF-36 39.6 (23.4) 44.1 (24.0) 0.03 
VAS 39.5 (22.6) 36.4 (23.4) 0.18 
Mental scales 
AIMS2 affect 3.65 (1.7) 3.17 (1.7) 0.008 
SF-36 68.2 (20.3) 73.3 (19.1) 0.01 
Fibromyalgia like symptoms (VAS) 
Muscle pain 45.2 (29.3) 36.3 (26.9) 0.003 
Concentration problems 23.1 (25.4) 17.5 (18.7) 0.02 
Numbness 28.9 (28.4) 16.0 (22.1) 0.001 
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founders (disease duration, age, education and concomitant dis- 
eases). 
Results: Mean (SD) age in the OA/RA groups was 61.6 
(5.6)/61.1 (6.0) years. Pain measures were numerically worse 
in OA than in RA and showed a statistically significant differ- 
ence for 2 (AIMS2 and SF 36) out of the 3 pain measures 
(table, two-sample t-test). Further levels of mental health sta- 
tus and fibromyalgia-like symptoms were also worse in OA than 
RA. Physical health status was significantly better in OA than 
RA,while social functioning, self-efficacy and utility were similar 
(data not shown). 
Conclusions: Female patients with hand OA experience more 
pain, more fibromyalgia-like symptoms and poorer mental health 
than women with RA of the same age. Our results point toward a 
difference between these two groups regarding the presence of 
soft tissue symptoms and/or that neuromuscular factors can have 
a different impact on pain perception in OA and RA patients. 
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A POWDER MADE FROM A SUBSPECIES OF ROSE HIP 
(ROSA CANINA), REDUCES WOMAC SYMPTOMS SCORE 
AS WELL AS CHOLESTEROL LEVEL IN PATIENTS 
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Objectives: The primary aim of the present study was to test 
if a herbal remedy made from a subspecies of rose hip (Rosa 
canina) might reduce symptoms of osteoarthritis after short time 
of treatment (3 weeks). Secondary efficacy variable was lipid 
metabolism. 
Methods: Ninety four patients with osteoarthritis of the hip or 
knee were enrolled in a randomized, placebo-controlled, double 
blind cross-over trial. 
Treatment: Forty seven patients were given five grams of the 
herbal remedy daily for a period of three months and the remain- 
ing patients were given a similar amount of identical placebo. The 
group initially treated with placebo was then changed to rose hip 
and vice versa for another three months period. Upon inclusion 
and after 3 weeks and 3 months of each treatment period pain, 
stiffness, disability and global severity of the disease was esti- 
mated on a WOMAC questionnaire. Cholesterol levels were esti- 
mated in the beginning and at the end of each treatment periods. 
Data were analyzed on the basis of intention to treat. 
Results: WOMAC pain significantly declined (p<0.02) as com- 
pared to placebo, when testing after 3 weeks of treatment. 
WOMAC disability, stiffness and global assessment of severity 
of the disease significantly declined after three months treatment 
(p< 0.04). In addition three months treatment resulted in a signif- 
icant decline in cholesterol (p<0.05). 
Conclusion: The present data suggest that the herbal remedy 
rose hip can alleviate symptoms of osteoarthritis in three weeks. 
The reduction in cholesterol can be related to treatment or is pos- 
sibly the result of enhanced physical activity caused by the reduc- 
tion of symptoms. 
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PROSPECTIVE, MULTI-CENTRE, RANDOMISED 
EVALUATION OF THE SAFETY AND EFFICACY OF FIVE 
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Rationale: Viscosupplementation by repeated intra-articular (IA) 
injections of hyaluronic acid (HA) is widely used in the treatment 
of knee osteoarthritis (OA). In some cases the number of injec- 
tions can be a limitating factor for the treatment. 
Aim: To assess different dosing regimens of hylan G-F 20, a high 
molecular-weight cross-linked derivative of HA, in the treatment 
of symptomatic knee OA. 
Methods: Prospective, multi-centre, open-label, randomised trial, 
including 100 patients (56 F, 44 M), aged 40 yrs or older (mean 
61.1, range 41-86), with unilateral symptomatic tibio-femoral OA 
(Kellgren-Lawrence grade II - III) who were randomised to 5 
groups to receive hylan G-F 20 IA injection of either 1 x 6 mL, 
1 x 4 mL, 2 x 4 mL 2 weeks apart, 3 x 4 mL 1 week apart, or 3 
x 2 mL 1 week apart. Target knee and systemic adverse events 
(AEs) were monitored throughout he study. Safety was also as- 
sessed by the patient using a 4-point side-effect rating scale. The 
primary endpoint for efficacy was a patient rated knee OA pain 
assessment using a 100mm VAS at 24 weeks following the first 
injection as compared to baseline. The secondary endpoints in- 
cluded WOMAC, patient and physician global assessments and 
knee OA pain assessment at all visits. Concomitant use of per- 
mitted rescue medications (paracetamol) was also assessed. The 
statistical analyses were performed on the ITT population. 
Results: All demographic parameters were similarly distributed 
between the 5 treatment groups. 
Safety: There were no serious device-related AEs.The safety pro- 
file of all treatment groups was relatively similar (pain, swelling, ef- 
fusion). Group 4 (3x4 mL) had the highest percentage of device- 
related local AEs (30%) whereas group 1 ( lx6  mL) and group 5 
(3x2 mL) had only 15%. 
Efficacy: There was a statistically significant improvement from 
baseline to week 24 in all endpoints for all treatment regimens. 
The study was not powered for statistical differences in efficacy 
between groups. However the groups 1, 4 and 5 consistently 
showed the greatest mean improvement. Table I summarizes the 
rankings of mean response to treatment for the primary and sec- 
ondary endpoints by treatment group. Notably, group 1 is ranked 
either first or second for all listed endpoints. 
Table I 
1X6mL 1X4mL 2X4mL 3X4mL 3X2mL 
Pain 2 4 5 3 1 
Womac pain 2 5 4 1 3 
Womac function 2 4 5 1 3 
Patient assessment 1 5 4 2 3 
Physician assessment 1 5 4 3 2 
Conclusion: Treatment with hylan G-F 20 was well tolerated in 
all groups up to a total dose of 12 mL.This study suggests that a 
single 6mL injection could be an alternative to the currently ap- 
proved 3 x 2mL treatment regimen. A double blind controlled trial 
is in progress to confirm these data. 
